Sam Cooper is the Co-Founder and Chief Technology Officer (CTO) of Phenomic AI, a biotechnology company pioneering the use of artificial intelligence to develop therapies targeting the tumor stroma in solid cancers. He co-founded Phenomic in 2017 alongside Oren Kraus, with the mission of improving patient outcomes in challenging cancers such as pancreatic and colorectal tumors.

Cooper earned his PhD from the Institute of Cancer Research in London, where he applied machine learning to biological systems, including the study of cell-cycle dynamics and protein behavior in live single cells. This interdisciplinary expertise laid the groundwork for Phenomic’s scTx® platform, which integrates single-cell RNA sequencing and deep learning to identify novel drug targets within the tumor microenvironment.